Shifting Focus in the Therapeutics of Immunobullous Disease (Q33737974)

29 July 2017

title

Shifting Focus in the Therapeutics of Immunobullous Disease (English)

1 reference

29 July 2017

Abhishek De

1

1 reference

29 July 2017

Asad Ansari

series ordinal

2

1 reference

29 July 2017

Nidhi Sharma

series ordinal

3

1 reference

29 July 2017

Aarti Sarda

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 2017

1 reference

Indian Journal of Dermatology

29 July 2017

published in

1 reference

29 July 2017

volume

62

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

282-290

1 reference

The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Persistence of anti-desmoglein 3 IgG( ) B-cell clones in pemphigus patients over years

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Omalizumab, an anti-immunoglobulin E antibody: state of the art.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Durable remission of pemphigus with a fixed-dose rituximab protocol

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Rituximab in the treatment of pemphigus vulgaris

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Efficacy and safety of rituximab treatment in Indian pemphigus patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Assessing the autoantibody levels in relation to disease severity and therapy response in pemphigus patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

The future of CD20 monoclonal antibody therapy in B-cell malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Linear IgA disease: successful application of immunoadsorption and review of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Rituximab in severe pemphigus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

A single cycle of rituximab for the treatment of severe pemphigus.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Rituximab: applications in dermatology.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Tolerability and safety of rituximab (MabThera).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Guidelines for the management of pemphigus vulgaris

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Bullous pemphigoid successfully treated with omalizumab

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Omalizumab therapy for bullous pemphigoid.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Rituximab for patients with refractory mucous membrane pemphigoid.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Steady-state generation of mucosal IgA plasmablasts is not abrogated by B-cell depletion therapy with rituximab

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Successful treatment of pemphigus vulgaris with etanercept in four patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

A randomized double-blind trial of intravenous immunoglobulin for pemphigus

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Therapy with Intravenous Immunoglobulins: Complications and Side-Effects

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5448263

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept

30 October 2018

1 reference

12 December 2020

Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab

1 reference

12 December 2020

Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption

1 reference

12 December 2020

Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption

1 reference

12 December 2020

Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption

1 reference

12 December 2020

Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?

1 reference

12 December 2020

Successful treatment of bullous pemphigoid with omalizumab

1 reference

12 December 2020

A pilot study of etanercept treatment for pemphigus vulgaris

1 reference

12 December 2020

Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept

1 reference

12 December 2020

Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)

1 reference

12 December 2020

Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita

1 reference

12 December 2020

Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients

1 reference

12 December 2020

A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita

1 reference

12 December 2020

Rituximab exerts a dual effect in pemphigus vulgaris

1 reference

12 December 2020

A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice

1 reference

12 December 2020

Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion

1 reference

12 December 2020

[New aspects on the pathogenesis of bullous pemphigoid]

1 reference

12 December 2020

Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

1 reference

12 December 2020

Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series

1 reference

12 December 2020

Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid

1 reference

12 December 2020

In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis

1 reference

12 December 2020

Rituximab for the treatment of corticosteroid - refractory pemphigus vulgaris with oral and skin manifestations

1 reference

12 December 2020

Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients

1 reference

12 December 2020

Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins

1 reference

12 December 2020

Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins

1 reference

12 December 2020

Identifiers

PMC publication ID

5448263

1 reference

29 July 2017

1 reference